In February 2026, CITEST Diagnostics Inc. launched the latest diagnostic innovations: a comprehensive suite of rapid tests and PCR detection kits designed to redefine accessible, reliable testing for clinical and public health settings worldwide. These solutions deliver precision, convenience, and scalability, empowering providers to act with confidence in diverse environments, from busy clinics to resource-limited communities.

Citest’s new rapid tests set a new standard for speed and simplicity, delivering actionable results in minutes without complex lab equipment. The G6PD Rapid Test is ideal for newborn screening and pre-medication safety, while the Respiratory Infectious Diseases Rapid Test enables customizable detection of multiple pathogens in a single test. The Rheumatoid Factor Rapid Test delivers 10-minute results, and the Leptospira IgM Rapid Test supports efficient screening in high-risk settings - all designed for minimal training and maximum impact.

Citest’s expanded PCR portfolio combines unmatched sensitivity and specificity with lyophilized formats that eliminate traditional barriers to molecular testing. These innovative kits offer game-changing advantages: ambient shipping removes cold-chain requirements, flexible small-volume packaging ensures ease of use, and an extended shelf life of up to 24 months guarantees long-term value. Covering critical pathogens like SARS-CoV-2 variants, influenza, RSV, monkeypox, STIs, and more - with select products bearing CE marking, this portfolio brings precision to every corner of the globe.

Ultimately, Citest’s 2026 diagnostic selections stand out for their user-centric design and market relevance. Rapid tests thrive in low-resource settings, while lyophilized PCR kits democratize access to molecular diagnostics. By merging portability, speed, and precision, these innovations empower healthcare providers, strengthen public health systems, and solidify Citest’s position as a trusted leader in diagnostic excellence.